29 C
Vientiane
Saturday, May 24, 2025
spot_img

/DISREGARD RELEASE: Celltrion/

This Week

We are advised by Celltrion that journalists and other readers should disregard the news release, Celltrion’s YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths, issued 21-May-2025 over PR Newswire.

Latest article